Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
24–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
With the exception of type 2 diabetes mellitus (T2DM), is in generally good health
Has a history of T2DM for ≥1 year at the time of screening based on self-reporting
Has a baseline HbA1C level of ≤10% at the time of screening
Has a stable weight (based on self-reporting) defined as ≤5 kg gain or loss of body weight for at least 3 months before Visit 1/Screening
T2DM treated with lifestyle modification alone or with stable doses (no significant change for ≥3 months from Visit 1/Screening, based on self-reporting) of ≤ 3 oral anti-diabetic medications and anticipated not to require dose adjustments during the study duration
Body mass index (BMI) between 25 and 40 kg/m2, inclusive
You may not be if
Has known systemic hypersensitivity to the MK-2828 drug substance or other nucleotide-binding, leucine-rich, protein 3 inhibitor (NLRP3i) based therapy, its inactive ingredients, or the placebo
Has a history of congestive heart failure (New York Heart Association \[NYHA\] Class 3 or 4)
Has a history of myocardial infarction, uncontrolled arrhythmias, cardiac revascularization, unstable peripheral arterial disease and/or stroke within 6 months of screening
History of significant multiple and/or severe allergies (e.g., food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e., systemic allergic reaction) to prescription or nonprescription drugs or food
Has type 1 diabetes mellitus or secondary types of diabetes
Has experienced complications of diabetes such as ketoacidosis, unstable diabetic retinopathy, or maculopathy
Has previous or planned (during the trial period) obesity treatment with surgery or a weight loss device
Clareo Health | Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)
